Indivior Announces Special Cash Dividend Pending Merger
News related to:Indivior Pharmaceuticals, Inc · 2 min read
RICHMOND, Va., Sept. 17, 2026 /CourierPR/ -- Indivior Pharmaceuticals, Inc., a leader in long-acting injectable treatments for opioid use disorder (OUD), has announced a special cash dividend. The dividend, totaling $8.13 per share of Indivior common stock, is payable to holders of record as of October 30, 2026. This dividend will be distributed to both Indivior common stockholders and holders of certain equity awards, contingent upon the successful completion of a merger with Supernus Pharmaceuticals, Inc.
The special dividend is subject to the closing of the previously announced merger transaction, which is expected to be consummated on or about November 2, 2026. Indivior's Board of Directors declared the dividend, with the payment anticipated to be made to eligible holders on or about November 6, 2026, assuming the merger is completed. Supernus stockholders will not be entitled to receive the dividend with respect to any Indivior common stock received as consideration in the merger.
Indivior, known for its focus on evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease, has been at the forefront of developing treatments that help individuals move toward long-term recovery. The company's commitment to this mission remains unwavering, as it continues to innovate and support those affected by OUD.
The dividend is contingent on the successful completion of the merger with Supernus, a move that is expected to bring significant benefits to both companies. The combined entity aims to leverage the strengths of both organizations to further advance the treatment of OUD and improve patient outcomes.
Indivior's special dividend underscores the company's financial health and its confidence in the future, despite the uncertainties surrounding the merger. The dividend is expected to provide a financial boost to both current and former employees, as well as to equity holders, pending the merger's successful completion.
The announcement of the special dividend comes as Indivior and Supernus continue to work towards the approval of the merger by their respective stockholders. The companies are also awaiting the adoption of the Merger Agreement by Supernus stockholders and the satisfaction or waiver of all conditions under the agreement. Indivior emphasizes that the special dividend will not be paid if the merger is not completed for any reason.
Indivior's focus on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease remains central to its mission. The company's commitment to this mission is reflected in its ongoing efforts to support individuals living with OUD and to contribute to the broader public health conversation around addiction and recovery.
As the companies move forward with the merger, Indivior's special dividend serves as a testament to the company's financial stability and its dedication to supporting those affected by OUD. The dividend is anticipated to provide a financial benefit to eligible holders, contingent upon the successful completion of the merger.